GenScript Biotech plans for the expansion of new manufacturing facility at Jiangsu, China. The facility supports the oligonucleotide and peptide production.
The new facility covering an area of 91,310 square feet features a highly automated clean-room facilities and services particularly in the areas of oligonucleotide and peptide synthesis for R&D and preclinical applications.
This includes qPCR oligos, NGS oligos, RNA oligos, DNA oligos, and more. These oligonucleotides are utilised in a wide range of applications, including molecular diagnostics, RNA interference (RNAi), and genome editing.
The addition of four new dynamic axial compression columns likely enhances the peptide synthesis capabilities. This expansion allows to achieve an average monthly production capacity of over 5 kilogrammes, which is a significant increase. Moreover, the new production lines will now enable to deliver up to 30,000 peptides per month.
The production facility equipped with high-throughput, large-scale synthesisers will allow for efficient production of oligonucleotides. It makes use of HPLC+ (High-Performance Liquid Chromatography) and PAGE+ (Polyacrylamide Gel Electrophoresis) purification processes to ensure stringent cross-contamination control and maintain high purity levels.
The expansion will increase the production capacity and provide even higher-quality oligonucleotides and peptides to researchers.
Name GenScript Biotech
Type New Constrcution